Oncorus to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Oncorus, Inc. (Nasdaq: ONCR) announced that CEO Theodore Ashburn will speak at two investor conferences on December 1, 2022. The events include a virtual fireside chat at the Evercore ISI HealthCONx Conference at 10:55 a.m. ET and an in-person chat at the Piper Sandler Healthcare Conference in New York at 12:30 p.m. ET. Webcasts of both sessions will be available on Oncorus' website, with replays archived for 90 days. Oncorus focuses on innovative viral immunotherapies aiming to improve cancer treatment outcomes.

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:

• Evercore ISI 5^th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.
• Piper Sandler 34th Annual Healthcare Conference: Fireside chat on Thursday, December 1, 2022 at 12:30 p.m. ET in New York, NY.

A webcast of each event can be accessed by visiting the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/. A replay of the webcast will be archived on Oncorus’ website for 90 days following the event.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to stimulate the immune system and transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) and self-amplifying viral RNA/LNP Platforms.

Designed as a next-generation viral immunotherapy, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity with immune stimulating payloads. Our lead HSV program, ONCR-177, currently in the clinic, is designed to be directly administered into a tumor, resulting in high local concentrations of therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering self-amplifying vRNA/LNP Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and LNP-based modalities designed to realize the potential of RNA medicines for cancer.

Please visit www.oncorus.com to learn more.

Investor Contact:
Stern Investor Relations
Julie Seidel
Julie.seidel@sternir.com

 

FAQ

What is the date and time for Oncorus' participation in the Evercore ISI HealthCONx Conference?

Oncorus will participate in the Evercore ISI HealthCONx Conference on December 1, 2022, at 10:55 a.m. ET.

Where will the Piper Sandler Healthcare Conference take place?

The Piper Sandler Healthcare Conference will take place in New York, NY on December 1, 2022.

How can I access the webcasts for Oncorus' investor conference presentations?

You can access the webcasts for Oncorus' presentations by visiting the Investors & Media section of their website.

What is the focus of Oncorus' research and development?

Oncorus focuses on developing next-generation viral immunotherapies to improve cancer treatment outcomes through innovative platforms.

How long will the webcasts of the investor conferences be available for replay?

The webcasts will be available for replay for 90 days following the events.